Telix Pharmaceuticals announces establishment of Japanese subsidiary


Telix Pharmaceuticals has announced the establishment of a wholly-owned operating subsidiary in Japan to support its Japanese clinical and radiopharmaceutical manufacturing activities.

Telix Co-Founder and CEO, Dr Christian Behrenbruch said the newly established entity – called Telix Japan – will help the company strengthen its commercial footprint in the growing Japanese market.

“Japan is one of the most important prospective markets for Telix’s products and our activities in Japan covers a range of manufacturing and collaboration activities with leading Japanese clinical sites and biopharmaceutical companies,” Mr Behrenbruch said.

“The Japanese radiopharmaceutical landscape is evolving rapidly, and we are pleased to have been able to hire two extremely high-caliber executives to lead our development and commercial activity.”

Telix, which recently announced a manufacturing partnership with Japan’s JFE Engineering Corporation, also announced the appointment of Dr Shintaro Nishimura and Dr Takeshi Oka as President and CEO, and Chief Medical Officer of Telix Japan, respectively.

“Telix has an exciting commercial opportunity for its products in Japan and Dr Oka and I are pleased to be leading the Company’s activities in the Japanese market, “Dr Nishimura stated.

“There is considerable interest in Telix’s oncology pipeline from our top nuclear medicine clinics and we hope to use this interest to obtain the additional data required to meet the marketing authorization requirements of the Pharmaceuticals and Medical Devices Agency (PMDA) to make Telix’s technology available to Japanese cancer patients.”

Telix is an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR).

The Company – which is listed on the ASX – is developing an advanced portfolio of oncology products that address significant unmet medical need in renal, prostate and brain cancer.

Image credit: